Lim Ming Han, Lord Anton R, Simms Lisa A, Hanigan Katherine, Edmundson Aleksandra, Rickard Matthew J F X, Stitz Russell, Clark David A, Radford-Smith Graham L
Department of Gastroenterology & Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Gut Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Ann Coloproctol. 2021 Oct;37(5):318-325. doi: 10.3393/ac.2020.08.26. Epub 2020 Sep 18.
We report outcomes and evaluate patient factors and the impact of surgical evolution on outcomes in consecutive ulcerative colitis patients who had restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) at an Australian institution over 26 years.
Data including clinical characteristics, preoperative medical therapy, and surgical outcomes were collected. We divided eligible patients into 3 period arms (period 1, 1990 to 1999; period 2, 2000 to 2009; period 3, 2010 to 2016). Outcomes of interest were IPAA leak and pouch failure.
A total of 212 patients were included. Median follow-up was 50 (interquartile range, 17 to 120) months. Rates of early and late complications were 34.9% and 52.0%, respectively. Early complications included wound infection (9.4%), pelvic sepsis (8.0%), and small bowel obstruction (6.6%) while late complications included small bowel obstruction (18.9%), anal stenosis (16.8%), and pouch fistula (13.3%). Overall, IPAA leak rate was 6.1% and pouch failure rate was 4.8%. Eighty-three patients (42.3%) experienced pouchitis. Over time, we observed an increase in patient exposure to thiopurine (P=0.0025), cyclosporin (P=0.0002), and anti-tumor necrosis factor (P<0.00001) coupled with a shift to laparoscopic technique (P<0.00001), stapled IPAA (P<0.00001), J pouch configuration (P<0.00001), a modified 2-stage procedure (P=0.00012), and a decline in defunctioning ileostomy rate at time of IPAA (P=0.00002). Apart from pouchitis, there was no significant difference in surgical and chronic inflammatory pouch outcomes with time.
Despite greater patient exposure to immunomodulatory and biologic therapy before surgery coupled with a significant change in surgical techniques, surgical and chronic inflammatory pouch outcome rates have remained stable.
我们报告了在一家澳大利亚机构连续26年接受回肠储袋肛管吻合术(IPAA)的溃疡性结肠炎患者的治疗结果,并评估了患者因素以及手术技术演变对治疗结果的影响。
收集包括临床特征、术前药物治疗和手术结果的数据。我们将符合条件的患者分为3个时间段组(时间段1,1990年至1999年;时间段2,2000年至2009年;时间段3,2010年至2016年)。感兴趣的结果是IPAA渗漏和储袋功能衰竭。
共纳入212例患者。中位随访时间为50(四分位间距,17至120)个月。早期和晚期并发症发生率分别为34.9%和52.0%。早期并发症包括伤口感染(9.4%)、盆腔脓毒症(8.0%)和小肠梗阻(6.6%),而晚期并发症包括小肠梗阻(18.9%)、肛门狭窄(16.8%)和储袋瘘(13.3%)。总体而言,IPAA渗漏率为6.1%,储袋功能衰竭率为4.8%。83例患者(42.3%)发生储袋炎。随着时间的推移,我们观察到患者使用硫唑嘌呤(P = 0.0025)、环孢素(P = 0.0002)和抗肿瘤坏死因子(P < 0.00001)的比例增加,同时向腹腔镜技术(P < 0.00001)、吻合器IPAA(P < 0.00001)、J型储袋构型(P < 0.00001)、改良两阶段手术(P = 0.00012)转变,且IPAA手术时临时性回肠造口术的比例下降(P = 0.00002)。除储袋炎外,手术和慢性炎症性储袋结果随时间无显著差异。
尽管患者术前接受免疫调节和生物治疗的比例增加,且手术技术发生了显著变化,但手术和慢性炎症性储袋的结果率保持稳定。